Abstract

Secondary metabolites from plants serve as defense against herbivores, microbes, viruses, or competing plants. Many medicinal plants have pharmacological activities and may, thus, be a source for novel treatment strategies. During the past 10 years, we have systematically analyzed medicinal plants used in traditional Chinese medicine and focused our interest on *Artemisia annua* L. (*qínghāo*, sweet wormwood). We found that the active principle of *Artemisia annua* L., artemisinin, exerts not only antimalarial activity but also profound cytotoxicity against tumor cells. The inhibitory activity of artemisinin and its derivatives towards cancer cells is in the nano- to micromolar range. Candidate genes that may contribute to the sensitivity and resistance of tumor cells to artemisinins were identified by pharmacogenomic and molecular pharmacological approaches. Target validation was performed using cell lines transfected with candidate genes or corresponding knockout cells. The identified genes are from classes with diverse biological functions; for example, regulation of proliferation (*BUB3*, cyclins, *CDC25A*), angiogenesis (vascular endothelial growth factor and its receptor, matrix metalloproteinase-9, angiotatin, thrombospondin-1) or apoptosis (*BCL-2*, *BAX*, NF-κB). Artesunate triggers apoptosis both by p53-dependent and -independent pathways. Antioxidant stress genes (thioredoxin, catalase, γ-glutamylcysteine synthetase, glutathione S-transferases) as well as the epidermal growth factor receptor confer resistance to artesunate. Cell lines overexpressing genes that confer resistance to established antitumor drugs (*MDR1*, *MRP1*, *BCRP*, dihydrofolate reductase, ribonucleotide reductase) were not cross-resistant to artesunate, indicating that artesunate is not involved in multidrug resistance. The anticancer activity of artesunate has also been shown in human xenograft tumors in mice. First encouraging experience in the clinical treatment of patients suffering from uveal melanoma calls for comprehensive clinical trials with artesunate for cancer treatment in the near future.

Key words

Angiogenesis · apoptosis · artemisinin · artesunate · cluster analysis · comparative genomic hybridization · microarrays · oxidative stress · pharmacogenomics

Introduction

Traditional Chinese medicine (TCM)

Medicinal herbs from TCM hold a unique position since an enormous variety of drugs from plant origin is founded on more than 5000 years of tradition [1], [2]. Hence, it is assumed that many ineffective prescriptions have disappeared thereby significantly improving the prospect for identifying novel active constituents from TCM [3], [4]. Our interest in natural products from TCM was triggered in the 1990s by sesquiterpene lactones of the artemisinin type from *Artemisia annua* L. [5]. The *Artemisia* genus is known to contain many bioactive compounds [6]. Apart from artemisinin, which is in the focus of the present review, we have analyzed cellular and molecular mechanisms of chemically characterized natural products derived from TCM. Among them were known compounds with still insufficiently defined modes of action, which were investigated by us with molecular biological and pharmacogenomic approaches, i.e., arsenic trioxide, ascari-
dol, berberine, cantharidin, cephalotaxine, curcumin, homoharringtonine, luteolin, isoosoprotein, scopoletin and others [7], [8], [9], [10], [11], [12], [13], [14], [15]. Furthermore, several novel bioactive compounds were described and analyzed in the course of our investigations, i.e., tetracontinsine A, tetracontinside A, B and C, the two novel α-tetralone derivatives berchemsianide A and B as well as the novel flavonoid quercetin-3-O-(2-acetyl-α-L-arabinofuranoside) [16], [17].

**Botany and geobotany of Artemisia annua L.**

This plant belongs to the family of Asteraceae and represents a strong aromatic shrub of 50–150 cm in height. The reproduction occurs by insect and self-pollination and wind distribution. The plant represents a typical neophyte in lowlands and hill countries in Asia and Europe with continental to subcontinental climate.

**History of artemisinin**

The first description of the Chinese herb *Artemisia annua* L. (sweet wormwood) dates back to the year 168 BC. The plant was mentioned in the prescriptions for 52 diseases in the Mawangdui tomb of the Han dynasty. The next historical tradition is from the year 1086 written by Shen Gua. In the “Handbook of Prescriptions for Emergency Treatment” Ge Hong (281 – 340 B.C.) recommended tea-brewed leaves to treat fever and chills. The “Compendium of Materia Medica” published by Li Shizen in 1596 cited Ge Hong’s prescription. In the course of the Vietnam war, the Chinese government started an antimalarial research program to systematically search for antimalarial TCM plants to support the Vietnamese army. As a result, artemisinin (qinghaosu) was identified in 1972 as the active antimalarial constituent of *Artemisia annua* L. [18], [19]. Today, artemisinin is widely used worldwide to combat otherwise drug-resistant *Plasmodium* strains, cerebral malaria, and malaria in children [20]. While *Artemisia annua* and artemisinin were regarded by the World Health Organization (WHO) with much reluctance for a long time, the full potential was recently recognized.

Besides the use in the treatment of malaria, the bioactivity of artemisinin and its derivatives is much broader. As shown in recent years, its potential application includes the treatment of infections of *Schistosoma*, *Pneumocystis carinii* [21], *Toxoplasma gondii* [22], human cytomegaloviruses, *Herpes simplex* viruses, and hepatitis B and C [23], [24], [25], [26]. In the 1990s, several groups recognized the cytotoxic activity of artemisinin and its derivatives against tumor cells [27], [28], [29], [30], [31]. The present review focuses on the antimalarial and anticancer activity of artemisinins.

**Antimalarial Activity**

Antimalarial drug resistance has spread and intensified during the past decades and represents a severe global challenge. It is estimated that 300–500 million human beings are infected each year and that 1.5–2.5 million individuals die of malaria annually [32], [33]. The development of novel drugs did not parallel this dramatic occurrence of malaria, which even aggravated the problem. Artemisinin and its derivatives are, therefore, promising new drugs on the horizon, which are expected to ease the malaria burden worldwide.

Drug combinations based on artemisinins offer an effective possibility to counteract drug resistance [34]. Combination regimes prolong the useful therapeutic life of existing antimalarial drugs. The probability that a mutant strain of *Plasmodium* simultaneously exerts resistance to two drugs with different modes of action and different therapeutic targets is low. Combinations of drugs are generally accepted to improve treatment efficacy and to delay the selection of drug-resistant parasites [35]. Indeed, it has been shown that the cure rate of artesunate or artemether in combination with mefloquine increased up to 95–100% compared to monotherapy with artemisinin derivatives. Other combinations, i.e., artemisinin derivatives and lumefantrine, also improved cure rates [35]. Despite the recommendation of the WHO to use artemisinin-based combination therapies, in order to avoid the emergence of artemisinin resistance, the overall use of such a combination dosage was still unsatisfactory [36]. For this reason, WHO banned artemisinin monotherapy in the year 2006.

Artemisinins proved to be valuable in drug combinations since they are able to reduce the number of parasites by approximately 10^4 per asexual cycle [37], [38]. Artemisinins are active within 48–72 h [39], [40]. This considerably reduces the number of parasites to be killed by a partner drug in a combination regimen. Since they inhibit the production of gametocytes, artemisinins are able to reduce transmission [41].

Another favorable feature of artemisinins is that they are active in the treatment of mild and severe forms of malaria. Severe malaria does not stop with clearing parasitemia. Even if parasites are cleared, the clinical symptoms associated with cerebral malaria may get worse. Besides the brain, other organs such as kidneys or lung can also be injured in severe malaria. Artemisinin has been proven as an effective anti-malarial drug for the treatment of cerebral malaria [42]. Artemisinin derivatives are generally well tolerated [43], [44]. Mild and reversible hematological and electrocardiographic abnormalities, such as neutropenia and first-degree heart block, were observed infrequently. Neurotoxicity, e.g., ataxia, slurred speech and hearing loss, have been reported in a few patients [45]. Due to their lack of severe side effects, artemisinins are also well suited for the treatment of malaria in children [46].

**Antitumor Activity of Artemisinin**

**Multifactorial nature of sensitivity and resistance to anticancer agents**

Rather than on the antimalarial activity of artemisinin and its derivatives, our own efforts were focused on the activity of these compounds towards cancer cells. During the past 10 years, we have analyzed molecular mechanisms of artemisinins. We were aware that analysis of the mode of action of a novel compound with activity against tumor cells is compromised by the fact that the response of tumor cells to cytotoxic agents is frequently determined by multiple factors and single mechanisms are not sufficient to account for a drug’s activity [47], [48], [49], [50], [51], [52]. Although anticancer drugs are extremely divergent in their chemical and physical structures and biological actions, a synopsis of the relevant mechanisms influencing drug effects allows their categorization into (i) those acting upstream of the ac-
tual drug target, (ii) those acting at critical target sites or (iii) those acting downstream of them [53], [54].

Mechanisms acting upstream include transporter proteins for uptake or excretion (i.e., ATP-binding cassette transporters, reduced folate carriers, and nucleoside transporters) and drug-metabolizing enzymes that activate, inactivate, or detoxify drugs (i.e., phase I/II enzymes). Metabolizing enzymes and transporter molecules often do not exhibit specificity for certain anticancer drugs but are operative towards a wide array of different xeno-biotic drugs including anticancer agents. Drug-metabolizing enzymes may influence pharmacokinetics and -dynamics.

Drug target sites for alkylating agents and platinum drugs are DNA (and DNA repair mechanisms), RNA (RNA synthesis inhibitors, i.e., actinomycin D) and specific proteins such as DNA topoisomerases I/II (camptothecins, anthracyclines, and epipodophyllotoxins), tubulins (Vinca alkaloids and taxanes) or enzymes of DNA biosynthesis (antimetabolites).

Mechanisms downstream of the actual drug targets and at distinct intracellular locations are operative after injury by drugs has been taken place. The most important downstream mechanisms are the diverse apoptosis pathways. Their deregulation may lead to drug resistance and survival of cancer cells despite target molecules have been successfully targeted by anticancer drugs [55], [56]. Programmed cell death is not only regulated by the proteins directly involved in the apoptotic cascade but also by external factors, i.e., by chemokines that act as “survival factors” involved in prevention of apoptosis and, hence, contributing to survival and drug resistance of tumor cells after chemotherapeutic insult [57], [58].

It is, therefore, reasonable to propose that the same is true for cytotoxic compounds from traditional Chinese medicine such as artemisinin and its derivatives (Fig. 1). Since we did not know the relevant upstream, target site, and downstream mechanisms of this class of drugs at the beginning of our studies, we applied pharmacogenomic approaches [59], [60], [61], [62].

**Upstream mechanisms – multidrug resistance**

Importantly, artemisinin and its derivatives are used to treat otherwise drug-resistant *Plasmodia* strains due to their lack of cross-resistance to these class of drugs [63]. Therefore, we addressed the question whether artemisinins are involved in the multidrug-resistance phenotype in tumor cells. Correlating the microarray-based mRNA expression of the multidrug resistance-conferring *ABCB1* gene (*MDR1*: P-glycoprotein) with the IC50 values for artemisinin and seven derivatives did not show significant relationships. Similarly, the flow cytometric measurement of the fluorescent probe rhodamine 123, which represents a functional assay for P-glycoprotein, did not reveal significant correlations to artemisinins [62]. To validate these results obtained by correlation analyses, we used cell lines overexpressing *MDR1/P*-glycoprotein and other drug resistance-conferring genes. We observed that artemesunate was similarly active towards drug-sensitive and multidrug-resistant cell lines [60], [64], [65], which overexpress *MDR1/P*-glycoprotein (CEM/ADR5000; CEM/VCR1000, CEM/VBL100), *MRP1* (CEM/E1000, HL60/AR) or *BCRP* (MDA-MB-231-BCRP). Likewise, methotrexate-resistant CEM/MTX1500LV cells with an amplification of the dihydrofolate reductase (*DHFR*) gene and hydroxyurea-resistant CEM/HUR90 cells with overexpression of ribonucleotide reductase (RRP2M) were not cross-resistant to artemesunate. Artesunate modulated the uptake of doxorubicin in *MRP1*-overexpressing CEM/E1000 cells, but not in *P*-glycoprotein-overexpressing CEM/VCR1000 cells [65].

**Upstream mechanisms – oxidative stress response**

In *Plasmodia*, the cleavage of the endoperoxide moiety of artemisinin is facilitated by heme-iron. Hemoglobin of erythrocytes serves as an amino acid source for *Plasmodium* trophozoites and schizonts. The parasites take up hemoglobin and degrade it in their food vacuoles [66], [67]. The release of heme-iron during hemoglobin digestion facilitates the cleavage of the endoperoxide moiety of artemisinin by an Fe(II)-Fenton reaction. Thereby, reactive oxygen species are generated, such as hydroxyl radicals and superoxide anions. They damage membranes of food vacuoles and lead to autodigestion [68], [69]. Furthermore, carbon-centered radical species are generated by the heme iron(II)-mediated decomposition of artemisinin [70], [71], [72]. These highly reactive molecules are able to alkylate heme and several *Plasmodium*-specific proteins [73], [74], [75], [76]. It has also been discussed, however, that heme iron(II) and oxidative stress are not the only determinants of artemisinin’s antimalarial activity [77].

![Upstream mechanisms](image-url)

**Fig. 1** Synopsis of mechanisms and candidate genes affecting the response of tumor cells to artesunate.

Effret T. Willmar Schwabe Award... Planta Med 2007; 73: 299–309
Focusing on the anticancer activity of artemisinin and its derivatives, we compared the baseline antioxidant mRNA gene expression in the NCI cell line panel with the IC₅₀ values for artesunate [78], [79], [80]. Our results are in favor of oxidative stress as a mechanism of action of artemunate against cancer cells. We found that thioredoxin reductase and catalase expression correlated significantly with the IC₅₀ values for artemunate. WEHI7.2 mouse thymoma cells selected for resistance to hydrogen peroxide or transfected with thioredoxin, manganese superoxide dismutase or catalase showed resistance to artemunate as compared to the parental cell line. The microarray-based mRNA expression of dihydrodiol dehydrogenase, γ-glutamylcysteine synthase (γ-GCS; GLCLR), glutathione S-transferases GSTM4, GSTT2, GSTZ1 and microsomal glutathione S-transferase MGST3 correlated significantly with resistance to artemunate in the NCI cell line panel. A tendency for correlation (0.05 < p < 0.1) was observed for GSTA1, GSTA2, GSTP1 and MGST1. MSC-HL13 cells transfected with cDNAs for heavy and light subunits of γ-GCS were more resistant to artemunate than mock transfected MSV-PC4 cells [60]. L-Buthionine sulfoximine, a γ-GCS inhibitor that depletes cellular glutathione pools completely, reversed artemunate resistance in MSV-HL13 cells [80].

As tumor cells contain much less iron than erythrocytes, but more than other normal tissues [81], the question arises as to whether iron may be critical for artemisinin’s action towards tumor cells. Cellular iron uptake and internalization are mediated by binding of the transferrin-iron complexes to the transferrin receptor (CD71) expressed on the cell surface membrane and by subsequent endocytosis. While most normal tissues are CD71-negative, CD71 is highly expressed in clinical tumors and is widely distributed among clinical tumors [82], [83]. We found that CD71 expression was much higher in CCRF-CEM and U373 tumor cells (48 – 95%) than in peripheral mononuclear blood cells of healthy donors (< 2 %) [84]. Iron(II) glycine sulfate (Ferro-sanol®) and transferrin increased the cytotoxicity of free artemunate, artemunate microencapsulated in maltosyl-β-cyclodextrin and artemisinin towards CCRF-CEM leukemia and U373 astrocytoma cells if compared with artemisinins applied without iron [84]. This effect was reversed by the monoclonal antibody RV510 against the transferrin receptor, which competes with transferrin for binding to the receptor. The IC₅₀ values for eight different artemisinin derivatives in the NCI cell lines were correlated with the microarray mRNA expression of 12 genes involved in iron uptake and metabolism. The mRNA expression of mitochondrial aconitase and ceruloplasmin (ferrooxidase) correlated significantly with the IC₅₀ values for artemisinins. Interestingly, exposure of artemisinin and its derivatives produces no or only marginal cytotoxicity to non-tumor cells. These results are in accordance with data from other authors [85], [86], [87]. We found that the growth of primary human fibroblasts is almost unaffected by artemunate concentrations up to 100 µM [23]. This implies that tumors that express more CD71 than normal cells might be more affected by combination treatments of transferrin or Ferrosanol® plus artemisinin derivatives. The finding that iron(II) glycine sulfate increased the action of artemisinins is interesting since Ferrosanol® has been in clinical use for many years. Hence, artemisinins might be safely applied in combination with Ferrosanol® in a clinical setting.

Target site interactions – protein alkylation
As stated above, artemisinins alkylate specific proteins in the Plasmodium parasites, i.e., heme, translationally controlled tumor protein (TCTP) and sarco/endoplasmic reticulum Ca²⁺ ATPases (SERCA) [73], [74], [75], [76], [88]. Whereas SERCA of Plasmodia may be affected by artemisinin, it does probably not alkylate human SERCA [76]. We have addressed the question whether TCTP may also be important for artemunate’s action in tumor cells. Interestingly, the microarray-based mRNA expression of TCTP correlated inversely with the IC₅₀ values for artemunate in the NCI tumor cell line panel. Tumor cell lines with high TCTP expression were sensitive to artemunate while low TCTP expression was associated with resistance to artemunate. Although a functional role of TCTP for the activity of artemisinins against tumor cells has not been shown, these results suggest such a role. TCTP represents a proliferation-related Ca²⁺-binding protein, which associates transiently with microtubules during the cell cycle [89]. It has also been implicated in malignant transformation and apoptosis [90], [91].

Despite these results, it should also be considered that artemisinin and its derivatives might alkylate many protein species. It is, therefore, possible that a more unspecific broad-spectrum alkylation of proteins in tumor cells rather than the specific alkylation of target proteins account for the growth-inhibitory effects of artemisinins.

Furthermore, the question arises whether artemisinins may alkylate other nucleophilic molecules in the cell such as DNA. It has been reported that artemisinin does not alkylate the DNA of malaria parasites [88]. In own experiments, we did not find that artemunate damages DNA of tumor cells at concentrations able to inhibit tumor cell growth (unpublished data).

Target site interactions – angiogenesis
The outgrowth of new blood vessels from pre-existing ones is crucial for tumors to gain access to sufficient amounts of oxygen and nutrients [92]. If tumors reach a size for which diffusion alone cannot supply enough oxygen and nutrients, a process termed angiogenesis is promoted by numerous pro-angiogenic or anti-angiogenic factors. As a consequence, inhibitors of angiogenesis were considered as interesting for cancer treatment [93], [94]. Artemisinin and its derivatives inhibit angiogenesis as shown by several groups including our own [95], [96], [97], [98], [99].

We showed that the microarray-based mRNA expression of 30 out of 90 angiogenesis-related genes correlated significantly with the cellular response to artemisinins [100]. Among this panel were many fundamental angiogenic regulators such as vascular endothelial growth factor C (VEGFC), fibroblast growth factor-2 (FGF1), matrix metalloproteinase 9 (MMP9), thrombospondin-1 (THBS1), hypoxia-inducing factor-α (HIF1A), angiogenin (ANG) and others. By means of hierarchical cluster analysis and cluster image mapping, we identified an expression profile that significantly determined the cellular resistance to several artemisinin derivatives, including artemunate, arteether, arteethermethyl and dihydroartemisinin ester stereoisomer 1. Using Matrigel plugs injected subcutaneously into syngenic mice, we found that artemunate indeed strongly reduced angiogenesis in vivo.
Inhibition of tumor angiogenesis represents, therefore, an important determinant of the anti-tumor effects of artemisinin and its derivatives.

**Downstream mechanisms – apoptosis**

In cluster analyses of microarray experiments, we found that the programmed cell death genes 2, 4, 8, and 9 (PDCD2, PDCD4, PDCD8, PDCD9), BCL2-associated athanogenes 1 and 3 (BAG1, BAG3), death-associated protein 6 (DAXX), MAP-kinase activating death domain (MADD), cell death–inducing DFFA-like effector β (CIDEB) and others are possible determinants of the tumor response to artemunate [60]. Since apoptosis is a common mechanism of cell death for most anti-cancer drugs, this may also apply for artemisinin and its derivatives. Indeed, artemunate induces apoptosis as first shown by us and subsequently by others [5], [101], [102], [103], [104], [105]. We identified several apoptosis-regulating genes whose mRNA expression correlated significantly with the I_{50} values for artemunate in the NCI cell lines [62]. WEHI7.2 cells transfected with the anti-apoptotic BCL2-gene were more resistant to artemunate than mock-vector-transfected control cells [79], indicating that artemunate may induce apoptosis via the intrinsic mitochondrial pathway of cell death. Furthermore, we found that artemunate acts via p53-dependent and –independent pathways in isogenic p53+/– p21/WAF1/CIP1+/+, p53–/– p21/WAF1/CIP1+/+ and p53+/– p21/WAF1/CIP1–/– colon carcinoma cells [60]. This was confirmed in a subsequent study with p53 wild-type TK6 and p53 mutated WTK1 lymphoblastic cells. In both cell lines, we observed a similar sensitivity towards artemunate [84].

**Downstream mechanisms – oncogenes and tumor suppressor genes**

Oncogenes and tumor suppressor genes frequently affect downstream processes in tumor cells, i.e., regulation of apoptosis, differentiation, proliferation etc. Therefore, we categorized the interrelationships between artemisinins and oncogenes/tumor suppressor genes as downstream mechanisms for systematic reasons in this review. The expression of several oncogenes and tumor suppressor genes correlated with the response to artemunate, including expression of epidermal growth factor receptor (EGFR), of the tumor growth factor β (TGFβ), of FBJ murine osteosarcoma viral oncogene homologue B (FOSB), of FOS-like antigen 2 (FOSL2), of the multiple endocrine neoplasia 1 gene (MEN1), of v-myb avian myeloblastosis viral oncogene homologue (MYB), of v-myc avian myelocytomatosis viral oncogene homologue (MYC), of c-src tyrosine kinase (CSK), of v-raf murine sarcoma viral oncogene homologue B1 (BRAF), of the RAS oncogene family members ARHC, ARHE, RAB2 and RAN, of the breast cancer susceptibility gene 2 (BRCA2) and of others [60].

EGFR represents an exquisite target for therapeutic interventions. It contributes to the development of drug resistance, and EGFR-coupled signal transduction pathways activate mitogenic and other cancer-promoting processes, e.g., proliferation, angiogenesis, and inhibition of apoptosis [106]. For this reason, we analyzed it in more detail. In agreement with the microarray data, we found that glioblastoma cells transfected with a deletion-activated EGFR cDNA were more resistant to artemunate than the control cells [60]. Furthermore, we found synergistic effects for the combination treatment with the EGFR tyrosine kinase inhibitor erlotinib (Tarceva, OSI-774) and artemunate in glioblastoma cells transfected with a deletion-activated EGFR cDNA and we found additive effects in wild-type EGFR transfectants [107]. We determined a profile of chromosomal gains and losses by comparative genomic hybridization in nine non-transfected glioblastoma cell lines. The correlation of the genomic aberrations in these cell lines with the I_{50} values for the combination treatment of artemunate and erlotinib pointed to certain genomic loci. The identified genes may serve as candidate genes for determining sensitivity and resistance. Currently, they are under further investigation.

**Preclinical and preliminary clinical studies**

The activity of artemisinin and its derivatives in vivo has been shown by several authors. Moore et al. [85] found that the growth of fibrosarcoma in Fisher 344 rats was significantly delayed by the daily application of the active metabolite of artemisinin, dihydroartemisinin, plus ferrous sulfate if compared to untreated control animals. Chen et al. [108] used the chorioallantoic membrane (CAM) assay in chicken eggs. It is widely accepted for analysis of the development of blood vessels in vivo. The CAM assay is particularly suited for the screening of angiogenesis inhibitors. Dihydroartemisinin significantly suppressed neoangiogenesis in this test system. These results correlate with results of our own investigations [98]. We soaked Matrigel plugs with vascular epithelial growth factor (VEGF), tumor necrosis factor-α (TNF-α) and heparin, which act as strong stimuli for angiogenesis. The Matrigel plugs were subcutaneously injected into nude mice. In control animals without artemunate treatment, a strong vascularization-based filling of the plugs with blood took place after four days. In contrast, a statistically significant reduction in Matrigel vascularization was observed in mice fed with artemunate in the drinking water. To determine the in vivo effects of artemunate on tumor growth, we subcutaneously injected KS-IMM Kaposi sarcoma cells to nude mice [98]. Whereas strong tumor growth was found in untreated mice, it was strongly suppressed in artemunate-treated animals. These results were subsequently confirmed by other authors. Disbrow et al. [109] found that dihydroartemisinin inhibited virus-induced tumor formation in vivo. Dogs infected with canine oral papillomavirus developed tumors in the oral mucosa. The tumor development was, however, significantly inhibited by topical application of dihydroartemisinin. Lai and Singh [110] induced breast cancer in rats by application of 7,12-dimethylbenz[a]anthracene (DMBA). In comparison to untreated control animals, rats fed with artemisinin showed delayed tumor development and decreased tumor size. Furthermore, fewer rats showed multiple breast tumors, and the occurrence of tumors was generally lowered.

The successful treatment of human xenograft tumors in nude mice with artemunate [98] encouraged us to apply artemunate in a clinical setting. We have treated two patients suffering from uveal melanoma on a compassionate-use basis after standard chemotherapy alone was ineffective in stopping tumor growth [111]. Generally, such tumor patients have a median survival time of 2–5 months. Upon use of artemunate, no additional side effects exceeding those caused by standard chemotherapy were observed indicating that artemunate was well tolerated. One pa-
tient experienced a temporary response after the addition of arte-nesate while the disease was progressing under standard ther-
apy with fotemustine alone. The patient died after 24 months.
The second patient first experienced a stabilisation of the disease 
following use of arteunate plus iron in combination with the 
standard drug dacarbazine followed by objective regressions of 
splenic and lung metastases. This patient is still alive 47 months 
after first diagnosis of stage IV uveal melanoma. This promising 
result indicates that arteunate might be a valuable adjuvant 
drug for the treatment of melanoma and other tumors in combi-
nation with standard chemotherapy. The treatment of a pituitary 
macroadenoma with artemether has been reported recently
[112]. Comprehensive clinical trials are needed to establish the 
efficacy of arteunate in cancer therapy.

**Mechanistic Basis for Common Modes of Action of 
Artemisinin in Plasmodium and Cancer**

**Reactive oxygen species, radical molecules and iron**

After absorption, artemisinin derivatives such as arteunate are 
metabolized in the liver by phase II enzymes (cytochrome P450 
monoxygenases) to dihydroxyartemisinin, which retains its 
bioactivity. Artemisinin itself is not converted to dihydroxyarte-
minisin [113], [114].

In malaria parasites, artemisinin acts by a two-step mechanism. 
It is first activated by intraparasitic heme-iron, which catalyzes 
the cleavage of the endoperoxide. The *Plasmodium* trophozoites 
and schizonts live within red blood cells. Here, they take up and 
digest hemooglobin. The heme-derived iron facilitates the 
cleavage of artemisinin's endoperoxide moiety by a Fe(II) Fenton re-
action. This results in the generation of reactive oxygen species 
and carbon-centered radical species [68], [69], [70], [71], [72]. 
Cleavage of the endoperoxide bond of artemisinin and its deriva-
tives leads to the alkylation of heme and some *Plasmodium*- 
specific proteins, including the *P. falciparum* translationally con-
trolled tumor protein (TCP), histidine-rich protein (42 kDa) and 
PFATP6, the sarco-/endoplasmic reticulum Ca2+ ATPase (SERCA) 
orthologue of *P. falciparum* [73], [74], [75]. Binding of artemisinin 
to the parasite’s DNA has not been observed [115].

As the iron storage in tumor cells is generally decreased compar-
ed to that of erythrocytes but increased in tumor cells if compar-
ed to normal cells [81], the question arises as to whether iron 
may also play a role in the inhibitory action of artemisinins to-
wards tumor cells [116]. The growth rate of a tumor was signifi-
cantly slowed down by daily oral administration of ferrous sul-
fate followed by dihydroartemisinin. No significant tumor growth retardation effect was observed in rats treated with ei-
ther dihydroartemisinin or ferrous sulfate alone. Drug treatment 
did not significantly affect body weight if compared with un-
treated tumor-implanted animals, and no apparent toxic effect 
was observed after drug treatment [85]. Iron(II) glycine sulfate 
(Ferrosanol®) and transferrin increased the cytotoxicity of free 
arternate, arteunate microencapsulated in maltosyl-β-cyclo-
dextrin and artesinimin towards CCRF-CEM leukemia and U373 
avastrocytoma cells if compared with that of artemisinin applied 
without iron [84]. Growth inhibition by arteunate and ferrous 
iron correlated with induction of apoptosis. The effect of ferrous 
iron and transferrin was reversed by the monoclonal antibody 
RVS10 against the transferrin receptor, which competes with 
transferrin for binding to the receptor. The IC50 values for eight 
different artemisinin derivatives in the NCI cell line panel were 
correlated with the microarray mRNAexpression of 12 genes in 
involved in iron uptake and metabolism in order to identify iron-
responsive cellular factors enhancing the activity of artesimi-
nins. This analysis pointed to mitochondrial aconitase and ceru-
loplasmin (ferroxidase). Interestingly, exposure of artesimisin 
and its derivatives produces no or only marginal cytotoxicity to 
normal peripheral blood mononuclear cells (PBMC).

**Role of the transcription factor NF-κB**

Artemisinin-type compounds belong to the class of sesqui-
perenes. This is a group of natural products present in medicinal 
plants all over the world with well-known anti-inflammatory ac-
tivities. Several investigations showed that the anti-inflamma-
tory activity is at least in part due to inhibition of the nuclear 
transcription factor κB (NF-κB) [117], [118], [119]. Molecular 
docking studies using the three-dimensional crystal structure of 
NF-κB revealed that many sesquiterpene lactones attack the cy-
steine-38 residue of the p54/NF-κB subunit [120], [121], [122], 
[123].

In 2002, we were the first to demonstrate that arteunate inhib-
bits NF-κB activity, leading to the inhibition of viral replication. 
NF-κB is involved in the transcriptional regulation of immediate 
early, early and late proteins of human cytomegalovirus (HCMV) 
necessary for viral replication [23]. Subsequent studies also sup-
port a role of artemisinin-type compounds in NF-κB inhibition. 
Aldieri et al. [124] found that artemisinin inhibits NF-κB activity 
and thereby blocks nitric oxide synthesis. Dihydroartemannin, a 
semisynthetic derivative of artemisinin, is also able to inhibit 
NF-κB [125]. Tripathi et al. [126] reported increased expression 
levels of the adhesion molecule ICAM-1 (intercellular cell adhe-
sion molecule-1) in human brain microvascular endothelial cells 
(HBMEC) after exposure to artemisinin. ICAM-1 is involved in se-
questration of *Plasmodium falciparum*-infected erythrocytes in 
the postcapillary brain endothelium. This represents a typical 
feature of cerebral malaria pathogenesis. Artemisinin reduced 
ICAM-1 expression in endothelial cells. As ICAM-1 expression 
is regulated by NF-κB, it is reasonable that artemisinin improves 
the therapeutic efficacy in cerebral complications during malaria 
infections. These results suggest that there is a common me-
chanistic basis for explaining the effects of artemisinin and its 
derivatives against malaria infections, viral infections and tumor 
cells.

**Biotechnological Approaches for the Production of 
Artemisinin**

The yield of artemisinin in wild populations of *Artemisia annua* is 
low (0.01 – 0.8%). Therefore, there is a considerable limitation to 
commercialization of the drug [127], [128]. Total synthesis of the 
product is feasible but time-consuming and expensive. Several 
synthesis routes with (-)-isopulegol, (+)-isolimenene or (R)-(+-)
pulegone as starting molecules have been described [129], [130], 
[131] (Fig. 2). The semi-synthetic production of artemisinin from 
its precursor artemisinic acid has also been shown. Artemisinic
Acid is present in 10-fold excess in the plants. Hence, the semisynthetic artemisinin yield is considerably higher than the isolation of artemisinin from plants. To preserve the natural resources of *Artemisia annua* plants, artemisinin-like endoperoxides, e.g., arteflene, have been synthesized chemically [132].

Other possibilities for meeting the high demand for artemisinin are found in the natural production of artemisinin by phytotherapeutic and agricultural approaches and in biotechnological approaches.

Phytotherapeutic and agricultural approaches [133], [134] allow:
- The cultivation of wild-type plants in fields and greenhouses.
- The breeding of high-yield cultivars. The artemisinin contents vary between individual plants even under comparable cultivation conditions (temperature, humidity, characteristics of the soil, etc.). Classical breeding techniques allow to cross high yield clones and to create synthetic variants of *Artemisia annua*.
- The cultivation of transgenic plants. Genetically modified plants deliver considerably higher amounts of artemisinin than wild-type plants.

In Africa, *Artemisia annua* plants are used in herbal teas to treat malaria. This has been critically discussed in terms of increased probability of resistance development against artemisinin [135]. The professional cultivation in fields and greenhouses allows the isolation artemisinin for further pharmaceutical processing.

Biotechnological approaches provide attractive possibilities for the large-scale production of artemisinin:
- Hairy root cultures of *Artemisia annua* can be generated by infection of roots with *Agrobacterium rhizogenes*. Hairy roots grow quickly, reach high densities and can produce significant amounts of secondary metabolites such as artemisinin [136], [137].
- The production of artemisinin in cell cultures in vitro [138].
- The expression of the biosynthetic pathway for artemisinin or related metabolites in genetically modified organisms, i.e. *E.coli* and *Aspergillus flavipes* [139], [140], [141] or *Saccharomyces cerevisiae* [142] has been reported. It is a prerequisite that the biosynthetic pathways for artemisinins in *Artemisia annua* are known. The biosynthesis of artemisinin has been elucidated, and the corresponding genes have been cloned. In brief, starting from the cytosolic MVA pathway (3R-mevalonic acid) and 3-acetyl-CoA on one side and from the plastidial DXP pathway (1-deoxy-d-xylulose 5-phosphate), pyruvate and glyceraldehyde 3-phosphate as starting molecules on the other side, several enzymatic steps lead to the synthesis of farnesyl diphosphate. Several further enzymatic reactions result in the generation of dihydroartemisinic acid and artemisinin (Fig. 3) [for a detailed representation of the biosynthesis of artemisinin, see reviews [143], [144]. If coding genes of these enzymes are transferred to microorganisms such as bacteria or yeast, it should be possible to reconstruct the biosynthetic pathway of artemisinin in these organisms.
Biotechnological approaches for the large-scale production of artemisinin represent a technical challenge. The obtainable yields should exceed the ones obtained by classical breeding methods. The artemisinin yield of one ton dry leaves of wild-type *Artemisia annua* is 6 kg per hectare. Time to grow is 100 – 120 days allowing three harvests per year under optimal conditions 18 kg artemisinin/hectare and year. With the use of genetically engineered organisms, it should be possible to produce 25 kg artemisinin within an 8-hours working day. This calculation is based on the assumption that engineered yeast will produce 100 – 150 mg artemisinin per liter culture medium or 100 – 150 g/1000 liter in an industrial set-up. The doubling time of yeast is about 1 h; hence, starting with 100 g artemisinin at time point 0 will result in 25.6 kg artemisinin after 8 h.

With the implementation of sophisticated biotechnological production techniques, it will be possible to meet the high demand for artemisinin for malaria treatment and hopefully in the future for cancer chemotherapy as well.

**Fig. 3** Biosynthesis of artemisinin in *Artemisia annua* L.

---

### References

Li WD, Dong YJ, Tu YY, Lin ZB. Dihydroartemisinin ameliorates lupus symptom of BXSB mice by inhibiting production of TNF-alpha and blocking the signaling pathway NF-kappaB translocation. Int Immunopharmacol 2006; 6: 1243–50.


